Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Context Therapeutics Q2 EPS $(0.25)

Context Therapeutics Q2 EPS $(0.25)

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.

Morgan Stanley Maintains Equal-Weight on Ares Management, Raises Price Target to $82

By Benzinga Newsdesk

October 31, 8:55 AM

Morgan Stanley analyst Michael Cyprys maintains Ares Management (NYSE:ARES) with a Equal-Weight and raises the price target from $76 to $82.

ARES

Earnings

A Preview Of Sportsman’s Warehouse’s Earnings

By Benzinga Insights

April 11, 10:00 AM

Sportsman’s Warehouse (NASDAQ:SPWH) is set to give its latest quarterly earnings report on Wednesday, 2023-04-12. Here’s what investors…

SPWH

News

Virgin Galactic Announces Crew For Return to Space In Late May

By Happy Mohamed

May 8, 8:39 AM

Virgin Galactic Holdings, Inc. (NYSE:SPCE) today announced the mission specialists who will take part in the upcoming Unity 25 mission. Unity 25 is the final assessment of the full spaceflight system and astronaut

SPCE

Meta’s Strategic Board Expansion: Broadcom’s CEO and Philanthropist Join as Company Sharpens AI Focus

By Anusuya Lahiri

February 15, 1:26 PM

Mark Zuckerberg expands Meta's board with two new directors, expressing enthusiasm for their contributions to long-term vision, including AGI.

AMZN

Context Therapeutics Q2 EPS $(0.25)

Related Posts

Morgan Stanley Maintains Equal-Weight on Ares Management, Raises Price Target to $82

A Preview Of Sportsman’s Warehouse’s Earnings

Virgin Galactic Announces Crew For Return to Space In Late May

Meta’s Strategic Board Expansion: Broadcom’s CEO and Philanthropist Join as Company Sharpens AI Focus